Calciphylaxis Market Overview

Calciphylaxis is a rare, painful condition that most commonly affects humans with moderate to severe kidney problems. It happens when calcium deposits form in the blood vessels and block blood flow to areas of the skin. Calciphylaxis is a poorly understood and highly morbid syndrome of vascular calcification and skin necrosis. According to the SMR Analysis, Calciphylaxis is a condition involving vascular calcification and cutaneous necrosis. The death rate is high, with more than 50 per cent of patients dying within one year of their diagnosis. The actual pathogenesis of calciphylaxis is unknown.

 

The Calciphylaxis Market is experiencing significant growth of XX% every year and is expected to continue its growth. Sanifit Therapeutics, Hope Pharmaceuticals, and Opko Health Inc. are well-established players in the Calciphylaxis Market. Sanifit Therapeutics is a global leader in the Calciphylaxis Market. Sanifit Therapeutics, with its main drug SNF472 in Phase 3 clinical trials, is at the forefront of creating a tailored therapeutic for calciphylaxis. The medicine's capacity to address the underlying cause of vascular calcification, combined with its orphan drug position, places Sanifit Therapeutics as a market leader. North America region held the dominant segment in the Calciphylaxis Market in 2023. Taiwan is the leading country in End-stage renal disease treatment in 2022.

 

The Calciphylaxis Market is mainly driven by Increasing clinical trials in the field of Calciphylaxis and Advancements in diagnostic techniques and improved awareness among healthcare providers are enhancing early detection and management strategies which leads to the rapid growth of Calciphylaxis Market globally in the forecasting year 2024-2030. Expensive Calciphylaxis Treatment is the main challenge in the Calciphylaxis Market. Based on the Treatment, Drug therapy holds the largest market share in the calciphylaxis market in 2023 because of drugs like Sodium thiosulfate, Bisphosphonate drugs, and Calcimimetics drugs.

 

To get more Insights: Request Free Sample Report

 

Calciphylaxis Market Dynamics

Calciphylaxis Market Drivers

Increasing clinical trials in the field of Calciphylaxis drive the Calciphylaxis Market.

Clinical studies are required to evaluate the safety and efficacy of new medicines and the efficacy of potential treatments and to gain regulatory approval. Increased clinical trials result in faster development of novel medicines, better understanding of the disease, and Enhanced treatment options. Clinical trials are increasing daily in Calciphylaxis because of the Rising Prevalence of End-Stage Renal Disease (ESRD) and chronic kidney disease (CKD), Increasing Awareness and Diagnosis, and Government Initiatives and Funding. Calciphylaxis is directly linked to ESRD and CKD, both of which are growing more common as a result of diabetes, hypertension, and an ageing population. The increased number of patients with these illnesses increases the demand for effective calciphylaxis therapy. Data on calciphylaxis trials is limited, due to the disease's rarity and the nature of the research reporting.

 

• According to the National Centre for Biotechnology Information, July 2024 shows a few actively recruiting trials, such as the Phase 3 CALCIPHYX trial of SNF472 (a phosphate binder) and the BEAT-Calci adaptive platform trial testing multiple interventions, the small number underscores the critical need for more research in calciphylaxis.

 

Advancements in diagnostic techniques and improved awareness to drive the Calciphylaxis Market Modern methods include more accurate and standardized skin biopsies with particular stains, as well as improved imaging modalities such as high-resolution ultrasonography, CT, and MRI, which allow for earlier and more reliable identification of calciphylaxis. Were drug such as SNF472 inhibits the development and progression of ectopic calcifications by binding to the growth sites of hydroxyapatite (HAP) crystals, the main component of calcification deposits, and in doing so blocks the formation and growth of HAP crystals in blood vessels, preventing CVC.

 

The development of particular diagnostic criteria and algorithms has improved differential diagnosis, resulting in more accurate diagnosis and suitable treatment. Companies are continually investing in the research and development of new diagnostic techniques for calciphylaxis.

 

• Sanifit's lead compound, SNF472, is a newly developed medication that inhibits hydroxyapatite crystallization, an essential phase in vascular calcification. It has shown promise in Phase 2 trials for delaying arterial calcification in dialysis patients. SNF472 is now in Phase 3 development for calciphylaxis, a serious cause of renal failure, with objectives focusing on wound healing and pain relief. It has also received orphan drug designation for this indication from both the FDA and EMA.

 

Calciphylaxis Market Challenges

Expensive Calciphylaxis Treatment - The high cost of calciphylaxis medication is an important barrier in the market, limiting patient access as well as limiting the expansion of the calciphylaxis market. This is primarily due to the disease's rarity, which has led to limited research and development of cost-effective treatment. Furthermore, the complex nature of calciphylaxis sometimes requires multidisciplinary care and long treatment periods, increasing expenditures. This financial load can put a strain on both healthcare systems and individuals, resulting in disparities in access to care and potentially affecting treatment outcomes.

 

• According to analysis, the annual cost of calciphylaxis treatment in the UK is around £72,000 per patient. The high cost per patient is likely due to multiple factors, including the complexity of calciphylaxis treatment, the need for lengthy treatment courses, the high cost of various drugs used in the calciphylaxis treatment, such as sodium thiosulfate, and frequent hospitalisations associated with calciphylaxis. According to the Clinical Kidney Journal, hospitalisations for calciphylaxis frequently last longer than 30 days.

 

Calciphylaxis Market Segment Analysis

Based on the Treatment, Drug therapy hold the largest market share in the calciphylaxis market in 2023. Sodium thiosulfate is the most dominating drug commonly used drug that dissolves calcium deposits and promotes wound healing. Sodium thiosulphate acts as a calcium-chelating agent and antioxidant for the treatment of calciphylaxis. The global market of sodium thiosulphate is projected to be around USD 114.33 million in 2023. Increasing incidences of chronic kidney failure disorders, mainly, calciphylaxis, are expected to boost the demand for sodium thiosulphate.

 

Sodium thiosulfate is also used as a dichlorination agent for swimming pools, aquariums, and water treatment plants to treat settled backwash water before releasing it into rivers and is widely used for gold extraction. Sodium thiosulfate is a reducing agent or antioxidant, neutralizing free radicals. The Asia-Pacific region will continue to dominate the sodium thiosulphate market in the forecasting year.

 

Calciphylaxis Market Regional Insights

North America dominates the calciphylaxis market due to significant advancements in healthcare, a strong economic environment, and the focus of research institutes on upgrading new versions of technology for new and advanced treatment methods. Furthermore, better hospital infrastructures and the availability of experienced medical professionals are driving market expansion. End-stage renal disease (ESRD), which is one of the primary causes of calciphylaxis, is prevalent in the United States. According to the Regents of the University of California, the number of cases of ESRD in the United States is increasing at a 5% annual rate.

 

Calciphylaxis primarily affects dialysis patients; this might be another important element driving market growth in the forecasting year. According to the University of California Regents, end-stage renal disease (ESRD) affects around 650,000 patients in the United States each year, with an estimated 2 million suffering globally. This could have a considerable impact on the global market for calciphylaxis treatment. Furthermore, the U.S. Renal Data System Annual Data Report shows that more than 660,000 Americans were treated for renal disease, with 468,000 on dialysis. This is expected to be another element that drives the calciphylaxis market.

 

Europe ranks second in the calciphylaxis market due to changing lifestyles, an increased emphasis on quick disease diagnosis and treatment, and an increase in disease incidence among senior citizens. The average incidence of ESRD in Europe is about 646,000 people which leads to 6,460 - 25,840 incidents of calciphylaxis in Europe.

 

The Asia Pacific calciphylaxis market is growing at the highest rate because of the large number of developing countries in the region, including India and China. These countries are fostering the development of the healthcare sector. The increasing cancer care population in developing countries will directly raise the demand for various diagnoses & treatment methods, which will increase calciphylaxis market growth.

Calciphylaxis Market Scope

Calciphylaxis Market
Market Size in 2023	USD 2.80 Bn.
Market Size in 2030	USD 4.49 Bn.
CAGR (2024-2030)	8.2%.
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Calciphylaxis Market Segments	by Treatment Drug Therapy Hyperbaric Calciphylaxis Therapy
	by Type Non-uremic calciphylaxis Ulcers and wounds Debridement of wounds
	by Diagnostics Skin Biopsy Lab Testing Imaging
	by End User Hospital and Clinics Homecare Ambulatory Centre

 

Calciphylaxis Market by Region

North America (United States, Canada, and Mexico)

Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)

Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)

South America (Brazil, Argentina, Rest of South America)

 

Calciphylaxis Market Key players

1. Sanifit Therapeutics
2. Hope Pharmaceuticals
3. Opko Health Inc.
4. Amgen
5. Kissei Pharmaceutical Co., Ltd
6. 3M
7. Mölnlycke Health Care
8. Smith & Nephew